Baird Medical Secures Pivotal Reimbursement Win for MWA
Successful reimbursement milestone strengthens device adoption and access strategy.
Shajini
UK Government Unlocks Game-Changing Drug Pricing Strategy
UK braces as drug pricing shifts dramatically in market access landscape.
Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
Poland Makes Historic Leap in Healthcare: Record Number of New Therapies Now Reimbursed
Poland’s Ministry of Health has announced its largest-ever reimbursement list update
FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors
FDA defines biosimilar PAS & CBE under BsUFA III
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)
Healthcare deal spotlight September 1 to 7, 2025
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.
NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.